Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

Journal of Clinical Investigation

Volumn 97, Issue 1, 1996, Pages 133-138

  D'Alessio, David A ^a   Vogel, Robin ^b   Prigeon, Ron ^a   Laschansky, Ellen ^a   Koerker, Donna ^b   Eng, John ^a   Ensinck, John W ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

enteroinsular axis; glucagon; glucose tolerance; incretin hormone; insulin secretion

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN;

ANIMAL EXPERIMENT; ARTICLE; BABOON; CONTROLLED STUDY; FOOD INTAKE; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030034912     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118380     Document Type: Article

References (45)

1. Drucker, D. 1990 Glucagon and the glucagon-like peptides. Pancreas. 5: 484-488.
2. Gokc, R . H.-C Fehmann, and B. Gokc. 1991. Glucagon-like peptide-1 (7-36) amide is a new incretin/enterogastrone candidate. Eur. J. Clin. Invest 21: 135-144
3. Mojsov, S., G. C. Weir, and J. F. Habener. 1987. Insulmotropin: glucagon-like peptide 1 (7-37) coencoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin Invest. 79:616-619.
4. Kreymann, B., M. A. Ghatei, G. Williams, and S. R. Bloom. 1987. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 2.1300-1303.
5. Holst, J. J. 1994. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology. 107:1848-1855.
6. Marks, R. M., L. M Morgan, J. A. Tredger, S. Deacon, J. Wright, and V. Marks. 1993. Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J. Endocrmol. 138:159-166.
7. McIntyre, N., C D. Holdsworth, and D. S. Turner. 1965. Intestinal factors in the control of insulin secretion. J. Clin Endocrinol 25:1317-1324.
8. Perley, M. J., and D. M. Kipnis. 1967 Plasma insulin responses to oral and intravenous glucose. Studies in normal and diabetic subjects. J. Clin Invest. 46:1954-1962.
9. Creutzfelt, W., and R. Ebert. 1985 New developments in the incretin concept. Diabetologia 28:565-573.
10. Komatsu, R., T. Matsuyama, M. Namba, N. Watanabe, H. Itoh, N. Kono. and S. Tarui. 1989. Glucagonostatic and insulinotropic action of glucagonlike peptide 1-(7-36)amide. Diabetes. 38:902-905.
11. Nauck, M. A., M. M. Heimesaat, C. Orskov, J J. Holst, R. Ebert, and W. Creutzfeldt. 1993. Preserved incretin activity of glucagon-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin. Invest. 91:301-307.
12. Gutniak, M., C Orskov, J. Holst, B Ahren, and S. Efendic 1992 Antidiabetogenic effect of glucagon-like peptide 1(7-36)amide in normal subjects and patients with diabetes mellitus. N. Engl J. Med 326:1316-1322
13. D'Alessio, D. A . S. E. Kahn, C. R. Leusner, and J. W Enstnck. 1994. Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin. Invest. 93 2263-2266.
14. Wheeler, M. B., M. Lu, J S. Dillon, X.-H. Leng C. Chen. and A. E. Boyd 1993 Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenyl cyclase and phospholipase-C. Endocrinology. 133:57-62.
15. Egan, J M., C Montrose-Rafizadeh, Y. Wang, M.Bernier, and J. Roth. 1994. Glucagon-like peptide 1 (7-36)amide enhances insulin-stimulated glucose metabolism in 3T3-LI adipocytes: one of several potential extrapancrealic sites of GLP-1 action Endocrinology 135:2070-2075.
16. Valverde, I. M. Morales, F. Clemente, M. I. Lopez-Delgado, E. Delgado, A. Perea, and M. L. Villanueva Penacarrillo 1994. Glucagon like peptide 1: a potent glycogenic hormone. FEBS Lett 349:313-316.
17. Villaneuva-Penacarrillo, M. L., A. I. Alcantara, F. Clemente, E. Delgado. and I Valverde 1994. Potent glycogenic effect of GLP-1 (7-36)amide in rat skeletal muscle, Diabetologia. 37:1163-1166.
18. Raufman, J.-P., L. Singh, G. Smgh, and J. Eng. 1992. Truncated glucagon-like peptide 1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267:21432-21437.
19. Goke, R., H -C. Fehman, T. Linn, H. Schmidt, M. Krause, J. Eng, and B, Goke. 1993 Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting β-cells. J Biol Chem. 268:19650-19655.
20. Wang, Z., R. M. Wang, A. A Owji, D. M. Smith, M. A. Ghatei, and S R. Bloom. 1995. Glucagon-like peptide 1 is a physiologic incretin in rat. J. Clin. Invest. 95:417-421.
21. Kolligs, F., H.-C. Fehmann, R. Goke. and B Goke, 1995 Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Diabetes. 44:16-19.
22. Bcard, J. C., R. N. Bergman, W. K. Ward, and D. Porte. 1986. The insulin sensitivity index in nondiabetic man Diabetes 35:362-369.
23. Ensinck, J W., C. Shepard, R. Dudl. and R Williams. 1971. Use of benzamidme as a proteolylic inhibitor in the radioimmunoassay of glucagon in plasma. J. Clin. Endocrinol & Metab. 35:463-467.
24. Eberts, T. J., R. H. Sample, M. R. Glick, and G. H. Ellis 1979. A simplified, colorimetric micromethod for xylose in serum or urine, with phlorogluci-nol. Clin Chem 25:1440-1443.
25. Zaharko, D., and L. Beck 1968 Studies of a simplified plasma insulin Immunoassay using cellulose powder. Diabetes. 17:444-457.
26. Orskov, C, and J. J. Holst 1987. Radio-immunoassays for glucagonlike peptides 1 and? Scand. J. Clin Lab. Invest 47:165-174.
27. Orskov, C., L. Rabenhoj, A. Wettergren, H. Kofod, and J. J. Holst 1994 Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide in humans. Diabetes. 43:535-539
28. Mentlein, R., B Gallwitz, and W. E. Schmidt. 1993. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide. glucagon-like peptide 1 (7-36)amide. peptide histidine methionine and is responsible for their degradation in human serum. Eur. J. Biochem. 214:829-835.
29. Deacon, C. F., A. H. Johnsen, and J. J. Holst 1995. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin. Endocrinol. Metab. 80:952-57.
30. Bergman, R. N., L. Phillips, and C. Cobelli. 1979. Physiologic evaluation of factors controlling glucose tolerance in man. J. Clin Invest 68:1456-1467.
31. Phillips, D. I. W., P. M. Clark, C. N. Hales, and C. Osmond. 1994. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabetic Medicine 11:286-292
32. Vaag, A., J. E. Henriksen, S Madsbad, N. Holm, and H. Beck-Nielsen. 1995. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J. Clin. Invest 95 690-698
33. Nagi, D. K . W. C. Knowler, M. A. Charles, Q. Z. Liu, R. L. Hanson. D. R. McCance, D. J. Pettitt. and P. H. Bennett. 1995. Early and late insulin response as predictors of NIDDM in Pima Indians with impaired glucose tolerance. Diabetologia. 38:187-192.
34. Seltzer, H. S., E. W. Allen, A. L. Herron, Jr., and M. T. Brennan 1967 Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J. Clin. Invest 46. 323-335.
35. Calles-Escandon, J , and D. C. Robbins 1987. Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes. 36:1167-1172.
36. Bruce, D. G., D J. Chisholm, L. H. Storlicn, and E. W. Kraegen. 1988. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes 37:736-744.
37. D'Alessio, D. A., R. Thirlby, E. Laschansky, H. Zebroski, and J. W Ensinck. 1993. Response of tGLP-1 to nutrients in humans. Digestion. 54:377-379
38. Holz, G. G., W. M. Kuhtreiber, and J F. Habener. 1993. Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1 (7-37). Nature (Lond.) 361:362-365.
39. Brelje, T. C., and R. L. Sorenson 1988. Nutrient and hormonal regulation of the threshold of glucose-stimulated insulin secretion in isolated rat pancreases. Diabetes. 123:1582-1590.
40. D'Alessio, D. A., R. L Prigeon, E C. Laschansky, R. E. Vogel, and J. W. Ensinck. 1995. Physiologic levels of GLP-1 promote glucose tolerance by both insulin-dependent and insulin-independent processes J. Invest. Med 43: 160a. (Abstr)
41. Wettergren, A., B. Schjoldager, P. E. Mortensen, J. Myhre, J. Christransen, and J. J. Holst. 1993. Truncated GLP-1 (pioglucagon 78-107 amide) inhibits gastric and pancreatic functions. Dig. Dis. Sci 38:665-673.
42. Nauck, M. A., N Kleine, C. Orskov, J. J Holst, B. Willms, and W Creutzfeldt. 1993 Normalization of fasting hyperglycemia by endogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:741-744.
43. Nathan, D. M., E. Schreiber, H. Fogel, S. MOJSOV, and J. F Habener 1992. Insulinotropic action of glucagonlike peptide-1-(7-37) in diabetic and nondiabetic subjects. Diabetes Care. 15:270-276.
44. Reaven, G. M., Y. D. I. Chen, A. Golay, A. L. M. Swislocki, and J. B Jaspan. 1987. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol. Metab. 64:106-110.
45. Orskov, C., J. Jeppesen, S. Madsbad, and J J. Holst. 1991. Proglucagon products in plasma of noninsulin-dependent diabetics and non-diabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin Invest. 87:415-423.